Clinical features and survival outcomes of patients with diffuse large B-cell lymphoma: analysis of web-based data from the Korean Lymphoma Working Party Registry

다국어 초록 (Multilingual Abstract)

Background This study aimed to survey the clinical spectrum of diffuse large B-cell lymphoma (DLBCL) in terms of epidemiology, pathologic subtypes, stage, and prognostic index as well as treatment outcomes.
Methods In 2007‒2008, 13 university hospitals evenly distributed in the Korean peninsula contributed to the online registry of DLBCL at www.lymphoma.or.kr and filed a total of 1,665 cases of DLBCL recorded since 1990.
Results Our analysis showed a higher prevalence of DLBCL in male than in female individuals (M:F=958:707), and extranodal disease was more common than primary nodular disease (53% vs. 47%). Among the 1,544 patients who had been treated with CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) or rituximab-CHOP (R-CHOP) therapy with or without radiation, 993 (63.9%) were alive, with 80% free of disease, 417 were dead (26.8%), with 13% free of disease, and 144 (9.3%) were lost to follow-up, with 23% free of disease. Age below 60 years, stage at diagnosis, international prognostic index (IPI) score regardless of age, and addition of rituximab to CHOP therapy in low- and low-intermediate-risk groups according to IPI scores significantly increased survival duration.
Conclusion The epidemiology, clinical spectrum, and biological behavior of DLBCL in Korea are similar to those observed in Western countries, and the advent of rituximab improved survival.

참고문헌 (Reference)

• 1 Swerdlow SH, "WHO Classification of tumours of haematopoietic and lymphoid tissues" IARC 2008
• 2 김진만, "WHO Classification of Malignant Lymphomas in Korea: Report of the Third Nationwide Study" 대한병리학회 45 (45): 254-260, 2011
• 3 Krause SW, "Treatment of B cell lymphoma with chemotherapy plus rituximab: a survival benefit can be demonstrated in the routine data of a regional cancer registry" 91 : 561-570, 2012
• 4 Sehn LH, "The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP" 109 : 1857-1861, 2007
• 5 Ziepert M, "Standard international prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era" 28 : 2373-2380, 2010
• 6 Oh MD, "Spectrum of opportunistic infections and malignancies in patients with human immunodeficiency virus infection in South Korea" 29 : 1524-1528, 1999
• 7 Pfreundschuh M, "Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)" 9 : 105-116, 2008
• 8 Cheson BD, "Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group" 17 : 1244-, 1999
• 9 Salles G, "Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium" 117 : 7070-7078, 2011
• 10 Guyomard S, "Prevalence and pattern of antinuclear autoantibodies in 347 patients with non-Hodgkin's lymphoma" 123 : 90-99, 2003
• 11 Komrokji RS, "Outcome of diffuse large B-Cell lymphoma in the United States has improved over time but racial disparities remain: review of SEER data" 11 : 257-260, 2011
• 12 Morton LM, "Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001" 107 : 265-276, 2006
• 13 Feugier P, "Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte" 23 : 4117-4126, 2005
• 14 Lee EH, "Liver cancer screening in Korea: a report on the 2008 National Cancer Screening Programme" 11 : 1305-1310, 2010
• 15 Kang J, "High prevalence of hepatitis B and hepatitis C virus infections in Korean patients with hematopoietic malignancies" 90 : 159-164, 2011
• 16 Møller MB, "Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation--a population-based study of 1575 cases" 124 : 151-159, 2004
• 17 López-Guillermo A, "Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin" 23 : 2797-2804, 2005
• 18 Yang BY, "Clinical characteristics and prognosis of diffuse large B-cell lymphoma" 27 : 174-176, 2005
• 19 Pfreundschuh M, "CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group" 7 : 379-391, 2006
• 20 Coiffier B, "CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma" 346 : 235-242, 2002